Every 10-Q that Ainos Inc (AIMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMD filings page.
Ainos, Inc., a Texas-based developer of AI-enabled olfactory sensing (AI Nose) and immune therapeutics, reported very limited revenue while remaining deeply loss-making for the quarter and six months ended June 30, 2026. Revenue was $152 in Q2 2026 and $313 in H1 2026, down sharply from $4,663 and $110,870 a year earlier as the company reduced VELDONA pet supplement sales and shifted AI Nose efforts toward industrial rather than healthcare-adjacent applications.
Net loss totaled $4.6M for Q2 2026 and $7.1M for H1 2026, compared with $4.1M and $7.4M in the prior-year periods, as operating expenses eased to $6.7M from $7.0M. Basic and diluted net loss per share was $0.62 for Q2 and $1.05 for H1 2026. Cash and cash equivalents increased to $1.4M at June 30, 2026 from $0.4M at December 31, 2025, mainly driven by a $2.8M short-term loan from ASE Test, Inc. and $0.6M of net equity raised under an at-the-market offering.
Total assets were $19.6M, while stockholders’ equity fell to $3.3M from $7.6M. Current liabilities rose to $16.3M, including $11.0M of convertible notes now classified as current and the new loan payable. With an accumulated deficit of $74.6M, ongoing operating losses, and dependence on external financing, the company states that substantial doubt exists about its ability to continue as a going concern. Operationally, Ainos continued to advance AI Nose deployments and validation in semiconductor manufacturing, robotics, industrial infrastructure, and healthcare environments, including work tied to an initial $2.1M backend semiconductor commercial arrangement, while progressing its VELDONA interferon programs selectively and pursuing partnering and out-licensing opportunities.
Ainos, Inc. reported Q1 2026 results showing minimal revenue and continued losses while shoring up liquidity with new financing. Revenue was just $161, down sharply from $106,207 a year earlier as the company shifted AI Nose activity from healthcare-adjacent uses toward earlier-stage industrial deployments.
The net loss narrowed to $2,459,800 from $3,286,022, helped by a 30% reduction in operating expenses, especially lower share-based compensation and SG&A. Cash and cash equivalents rose to $2,841,422 from $417,353 at year-end, driven by a new related-party loan of about $2,812,940 and $601,600 of net proceeds from an at-the-market equity program.
Total liabilities increased to $16,389,637, including $11,000,000 of related-party convertible notes, while stockholders’ equity declined to $5,691,946. Management states that recurring losses, an accumulated deficit of $69,980,128, and dependence on future financings create “substantial doubt” about the company’s ability to continue as a going concern.
Ainos, Inc. (AIMD) filed its Q3 2025 10‑Q, reporting continued operating losses with limited cash. Nine‑month revenue was $113,037, up from $20,729, driven mainly by VOC sensing co‑development and modest VELDONA Pet sales. Net loss was $10,302,714, and operating loss reached $9,692,751. Cash and cash equivalents were $1,128,217 at September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern.
To support liquidity, Ainos used its at‑the‑market program with H.C. Wainwright, selling 674,867 shares for $1,852,895 in net proceeds through September 30 and an additional 18,837 shares for $68,151 from October 1 to November 13. Shares outstanding were 4,793,797 as of September 30 and 4,812,634 as of November 13, 2025, following a 1‑for‑5 reverse split effective June 30. R&D expenses were $5,626,514 and SG&A $4,159,627 for the first nine months, reflecting ongoing investment in AI Nose, POCT, and VELDONA development while the business advances pilot deployments and partnerships.